Steve Seedhouse

“First, I just wanted to ask on Curvaya and if you can give us a sense of what actually were the sales for that product, maybe in 2025, 2026, year to date, and whether it's growing or if it's stable or even declining slightly in recent years before you take over.”

“Just wanted to ask first on the upcoming, on the forthcoming of VMS data, what in your view is a clinically meaningful improvement in the VMS severity just in the context of that, I think, three-point ordinal scale that's used for assessing severity?”

“I wanted to first just get your expanded thoughts on the titration schema that you're using in this maintenance study and if you're expecting, I guess, at a high level, if it'll mitigate or increase the GI adverse events that you saw in Phase 2.”

“And thanks for the color on the commercial preparations in the U.S. I actually just wanted to ask about, on the other side, ex-U.S., particularly in Europe, But sort of how you're thinking about filing timeline, you know, launch strategy, partnering strategy, if relevant, would love your current thinking on the ex-US…”

“First is just on the change from four to eight sub-Q maintenance cohorts in the ongoing study. I was hoping you could just elaborate on what, like, doses and intervals the new eight cohorts. are testing.”